Capricor Therapeutics, Inc.
Deramiocel
Duchenne muscular dystrophy
Countdown
47days
FDA decision · Aug 22, 2026
What's at stake
The FDA's approval decision on Deramiocel for Duchenne muscular dystrophy is due Aug 22, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“The U.S. Food and Drug Administration has granted Deramiocel Priority Review, with a target PDUFA action date of August 22, 2026.”